Finally, these obtained findings encourage Trim31 as a feasible therapeutical target for NAFLD/NASH and associated-metabolic disorders which might be accountable to diagnosis and therapeutic schemes. The gene discussed is TRIM31; the disease is metabolic dysfunction-associated steatotic liver disease.